Scott syndrome dogs have impaired coated-platelet formation and calcein-release but normal mitochondrial depolarization [1]

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 9, 2007, Pages 1972-1974

  Brooks, Marjory B ^a   Catalfamo, J L ^a   Friese, P ^b   Dale, G L ^b  

^a Department of Obstetrics Gynecology   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CALCEIN; CONVULXIN; THROMBIN;

ANIMAL CELL; APOPTOSIS; CONTROLLED STUDY; DOG; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LETTER; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCOTT SYNDROME; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPOIESIS; THROMBOGENESIS;

ANIMALS; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; DOGS; FLUORESCEINS; MITOCHONDRIA;

EID: 34548080000     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02683.x     Document Type: Letter

References (13)

1. Dale GL. Coated-platelets: An emerging component of the procoagulant response. J Thromb Haemost 2005; 3: 2185-92.
2. Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood 1997; 90: 2615-25.
3. Kempton CL, Hoffman M, Roberts HR, Monroe DM. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol 2005; 25: 861-6.
4. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: Effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000; 95: 1694-702.
5. Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost 2007; 5: 774-80.
6. Remenyi G, Szasz R, Friese P, Dale GL. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol 2005; 25: 467-71.
7. Brooks MB, Catalfamo JL, Brown HA, Ivanova P, Lovaglio J. A hereditary bleeding disorder of dogs caused by a lack of platelet procoagulant activity. Blood 2002; 99: 2434-41.
8. Weiss HJ. Scott syndrome: A disorder of platelet coagulant activity. Semin Hematol 1994; 31: 312-9.
9. Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004; 1636: 119-28.
10. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, Clemetson KJ, Alberio L. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415: 175-9.
11. Jobe SM, Wilson KM, Leo L, Molkentin JD, Lentz SR, DiPaola J. Critical role for cyclophilin D and mitochondrial permeability transition pore (MPTP) in platelet activation. Blood 2006; 108: 435a (Abstract).
12. Albrecht C, McVey JH, Elliott JI, Sardini A, Kasza I, Mumford AD, Naoumova RP, Tuddenham EG, Szabo K, Higgins CF. A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome. Blood 2005; 106: 542-9.
13. Catalfamo JL, Brooks MB, Ammersbach M, deMaster A. Platelet ABCA1 expression is normal in Scott syndrome dogs. Blood 2006; 108: 57b (Abstract).